Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2020 - 2026)

Catalyst Pharmaceuticals filings provide 11 years of Long-Term Deferred Tax readings, the most recent being $55.1 million for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax rose 14.29% to $55.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $55.1 million, a 14.29% increase, with the full-year FY2025 number at $52.8 million, up 14.76% from a year prior.
  • Long-Term Deferred Tax hit $55.1 million in Q1 2026 for Catalyst Pharmaceuticals, up from $52.8 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $55.1 million in Q1 2026 to a low of $18.7 million in Q4 2022.
  • Median Long-Term Deferred Tax over the past 5 years was $38.3 million (2024), compared with a mean of $36.9 million.
  • Biggest five-year swings in Long-Term Deferred Tax: tumbled 30.33% in 2022 and later soared 95.05% in 2023.
  • Catalyst Pharmaceuticals' Long-Term Deferred Tax stood at $18.7 million in 2022, then soared by 95.05% to $36.5 million in 2023, then rose by 25.83% to $46.0 million in 2024, then grew by 14.76% to $52.8 million in 2025, then increased by 4.44% to $55.1 million in 2026.
  • The last three reported values for Long-Term Deferred Tax were $55.1 million (Q1 2026), $52.8 million (Q4 2025), and $48.3 million (Q3 2025) per Business Quant data.